sq-29548 has been researched along with dazmegrel* in 13 studies
13 other study(ies) available for sq-29548 and dazmegrel
Article | Year |
---|---|
Functional significance of pharmacological blocking of renal thromboxane in old and young rat kidneys.
Topics: Aging; Animals; Bridged Bicyclo Compounds, Heterocyclic; Fatty Acids, Unsaturated; Glomerular Filtration Rate; Hydrazines; Imidazoles; Kidney; Male; Rats; Rats, Sprague-Dawley; Receptors, Thromboxane; Thromboxanes | 1994 |
Role of prostaglandin H2-thromboxane A2 in responses of cerebral arterioles during chronic hypertension.
The goal of this study was to determine the role of prostaglandin H2-thromboxane A2 (PGH2-TxA2) in altered responses of cerebral arterioles during chronic hypertension. Diameter of pial arterioles was measured during suffusion with ADP, acetylcholine, and nitroglycerin using intravital microscopy in Wistar-Kyoto (WKY) normotensive rats and spontaneously hypertensive rats (SHR) (8-10 mo old). ADP (100 microM) increased pial arteriolar diameter by 21 +/- 3% (means +/- SE) in WKY and only by 7 +/- 3% in SHR. Acetylcholine (10 microM) increased diameter 10 +/- 2% in WKY and, in contrast, reduced diameter 7 +/- 3% in SHR. Nitroglycerin produced similar vasodilatation in WKY and SHR. We then examined whether impaired dilatation of cerebral arterioles in SHR to ADP and acetylcholine may be related to activation of the PGH2-TxA2 receptor. SQ 29548, a specific PGH2-TxA2 receptor antagonist, restored vasodilatation in response to ADP in SHR toward that observed in WKY and reversed vasoconstriction to vasodilatation in response to acetylcholine in SHR. SQ 29548 did not alter responses in WKY. Thus these findings suggest that impaired responses of cerebral arterioles to ADP and acetylcholine during chronic hypertension may be related to the activation of the PGH2-TxA2 receptor. Topics: Acetylcholine; Adenosine Diphosphate; Animals; Arterioles; Brain; Bridged Bicyclo Compounds, Heterocyclic; Chronic Disease; Fatty Acids, Unsaturated; Hydrazines; Hypertension; Imidazoles; Male; Nitroglycerin; Prostaglandin Endoperoxides, Synthetic; Prostaglandin H2; Prostaglandins H; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Thromboxane A2; Vasodilator Agents | 1992 |
Thromboxane mediates renal hemodynamic response to infused angiotensin II.
Since we had found that angiotensin II (Ang II), but not phenylephrine (PE), increased the excretion of thromboxane (Tx) and raised mean arterial pressure (MAP) by a Tx-dependent mechanism, we tested the role of TxA2 in mediating Ang II-induced changes in renal hemodynamics. For series 1, groups of anesthetized rats received an i.v. infusion of Ang II (50 ng.kg-1.min-1). When infused with a vehicle, Ang II increased MAP, renal vascular resistance (RVR) and the excretion of TxB2 factored by GFR. A PGH2-TxA2 receptor antagonist, SQ-29,548, or three days of pretreatment with a TxA2 synthase inhibitor UK-38,485, which reduced excretion of TxB2 by 80%, blunted the rise in MAP and RVR induced by Ang II. In contrast, three days of pretreatment with indomethacin did not alter the renal vascular response to Ang II. For series 2, groups of rats received Ang II at a higher rate (500 ng.kg-1.min-1) while the RPP was stabilized at +11 to +15 mm Hg with a suprarenal aortic clamp. SQ-29,548 and UK-38,485 both prevented Ang II-induced reductions in GFR and blocked 80% of the increase in RVR. For series 3, infusions of phenylephrine at an equipressor dose to series 2 of 30 micrograms.kg-1.min-1 with control of RPP at +14 mm Hg also increased RVR but this was not blunted by SQ-29,548.. 1.) infusion of Ang II increases excretion of filtered TxB2, causes dose-dependent increases in RVR and, at high doses, reduces GFR.(ABSTRACT TRUNCATED AT 250 WORDS) Topics: Angiotensin II; Animals; Blood Pressure; Bridged Bicyclo Compounds, Heterocyclic; Fatty Acids, Unsaturated; Hemodynamics; Hydrazines; Imidazoles; Male; Rats; Rats, Inbred Strains; Receptors, Prostaglandin; Receptors, Thromboxane; Renal Circulation; Thromboxane A2; Thromboxane-A Synthase; Vascular Resistance | 1991 |
Contrasting effect of thromboxane synthase inhibitors and a thromboxane receptor antagonist on the development of angiotensin II-salt-induced hypertension in rats.
This study was designed to contrast the effects of prolonged treatment with a thromboxane (Tx) synthase inhibitor (UK 38485 or SC 41156) and a Tx receptor antagonist (SQ 29548) on the development of angiotensin II (Ang II)-salt-induced hypertension. Ang II infusion (125 ng/min i.p. for 12 days) in rats drinking 0.15 M NaCl resulted in severe hypertension accompanied by proteinuria, reduction of urinary creatinine excretion and augmentation of urinary TxB2 excretion and TxB2 release from aortic rings and renal cortex slices. In saline-drinking rats undergoing Ang II infusion, the concomitant administration by gavage of UK 38485 (100 mg/kg/day) or SC 41156 (25 mg/kg/day) reduced serum and urinary TxB2 and TxB2 release from aortic rings and/or renal cortex slices, but it was without effect on the development of hypertension. In contrast, concomitant infusion of SQ 29548 (4.2 mg/24 hr s.c.) significantly attenuated the increase of blood pressure produced by the infusion of Ang II in saline-drinking rats. This effect of SQ 29548 may be the consequence of blockade of the actions of one or more endogenous eicosanoids that increase blood pressure by a mechanism(s) involving interaction with TxA2 receptors. This implies that pressor eicosanoids play a contributory role in the development of severe Ang II-salt hypertension. Topics: Angiotensin II; Animals; Blood Pressure; Bridged Bicyclo Compounds, Heterocyclic; Fatty Acids, Unsaturated; Hydrazines; Hypertension; Imidazoles; Male; Rats; Rats, Inbred Strains; Receptors, Prostaglandin; Receptors, Thromboxane; Sodium Chloride; Thromboxane A2; Thromboxane-A Synthase | 1990 |
Bradykinin-induced vasoconstriction of rat mesenteric arteries precontracted with noradrenaline.
1. Administration of bradykinin caused dose-dependent vasoconstriction in rat isolated perfused mesenteric arteries precontracted with noradrenaline. 2. The vasoconstrictor response was not mediated by BK1-bradykinin receptors. 3. Inhibition of cyclo-oxygenase with indomethacin, aspirin or meclofenamate abolished the vasoconstrictor effect of bradykinin, showing that a member of the arachidonic acid cascade may be involved. 4. Inhibitors of thromboxane synthesis (imidazole and UK 38485) did not affect or only reduced the bradykinin-induced vasoconstriction. 5. The endoperoxide H2/thromboxane A2 receptor antagonist SQ 29548 significantly reduced the vasoconstrictor effect of bradykinin, but did not affect the vasoconstrictor response to noradrenaline, adrenaline, vasopressin, 5-hydroxytryptamine or prostaglandins. 6. The eicosanoid(s) that mediate bradykinin-induced vasoconstriction appear to be synthesized outside the arterial endothelium. 7. The data suggest that the vasoconstrictor effect of bradykinin in the rat isolated mesenteric artery is mediated by vasoconstrictor arachidonic acid metabolites including the cyclic endoperoxides and/or the thromboxanes. Topics: Animals; Aspirin; Bradykinin; Bridged Bicyclo Compounds, Heterocyclic; Cyclooxygenase Inhibitors; Eicosanoids; Endothelium, Vascular; Fatty Acids, Unsaturated; Hydrazines; Imidazoles; In Vitro Techniques; Indomethacin; Meclofenamic Acid; Mesenteric Arteries; Norepinephrine; Rats; Receptors, Prostaglandin; Receptors, Thromboxane; Thromboxane A2; Thromboxane-A Synthase; Vasoconstriction | 1990 |
Renal function in rats with angiotensin II-salt-induced hypertension: effect of thromboxane synthesis inhibition and receptor blockade.
This study was designed to assess the contribution of thromboxane (Tx) A2 to the pathogenesis of renal dysfunction in rats with angiotensin II (Ang II)-salt hypertension. Hypertension was induced in rats drinking 0.15 mol/l NaCl by infusion of Ang II (125 ng/min, intraperitoneally) for 12 days. Relative to values in water- and saline-drinking rats without Ang II infusion, rats with Ang II-salt hypertension exhibited increased renal vascular resistance, decreased renal blood flow, and increased renal excretion and glomerular synthesis of TxB2. Treatment with an inhibitor of TxA2 synthesis, UK 38,485, had no effect on renal function in normotensive and hypertensive rats. Similarly, the TxA2 and prostaglandin endoperoxide antagonist SQ 29,548 did not affect renal function in normotensive rats. In contrast, in rats with Ang II-salt hypertension of 12 days' duration, SQ 29,548 caused a reduction in renal vascular resistance, allowing for maintenance of renal blood flow in the face of an accompanying reduction in blood pressure. A comparable reduction in renal perfusion pressure, produced by constriction of the abdominal aorta above the renal arteries, was not accompanied by a reduction in renal vascular resistance in Ang II-salt hypertensive rats. Therefore, the SQ 29,548-induced lowering of renal vascular resistance is attributable not to renal blood flow autoregulation, but to blockade of the renal vasoconstrictor actions of TxA2 and/or prostaglandin endoperoxides. This interpretation implies that pressor eicosanoids contribute to increase renal vascular resistance in rats with severe Ang II-salt hypertension. Topics: Angiotensin II; Animals; Bridged Bicyclo Compounds, Heterocyclic; Fatty Acids, Unsaturated; Hydrazines; Hypertension; Imidazoles; Kidney; Male; Rats; Rats, Inbred Strains; Sodium, Dietary; Thromboxane A2; Thromboxane-A Synthase; Vascular Resistance | 1990 |
Thromboxane mediation of the pressor response to infused angiotensin II.
The role of thromboxane A2(Tx) in mediating the pressor response to angiotensin II (AII) was studied in anesthetized rats. Intravenous AII (500 ng/kg/min) increased mean arterial pressure (MAP) by 35 +/- 3 mm Hg and increased the excretion of prostaglandin PGE2, the metabolites of prostacyclin (6kPGF1 alpha) and Tx (TxB2) (P less than .05). A similar pressor infusion of the alpha 1-adrenoreceptor agonist phenylephrine (PE) increased the excretion of PGE2 and 6kPGF1 alpha but not TxB2. The increases in MAP and prostaglandin excretion produced by AII were reversed by the AII-receptor antagonist saralasin (10 micrograms/kg/min) while those produced by PE were reversed by the alpha-adrenoreceptor antagonist phenoxybenzamine (250 micrograms/kg). The Tx receptor antagonist, SQ-29,548 (8 mg/kg) attenuated (P less than .0001) the AII-induced rise in MAP (13 +/- 1 mm Hg) but did not modify the pressor response to PE. The Tx synthetase inhibitor, UK-38,485 (50 mg/kg/d) given for 3 days, reduced basal TxB2 excretion by 75% and also attenuated (P less than .001) the AII-induced rise in MAP (11 +/- 2 mm Hg). However, when given 40 min before the AII infusion, UK-38,485 did not attenuate the pressor response. In separate groups of rats, the log dose-response curve for bolus intravenous injection of AII was shifted to the right by SQ-29,548 while that for PE was unaffected.. 1) AII releases Tx; 2) Tx release is not secondary to hypertension; and 3) Tx can mediate up to two-thirds of the short-term pressor response to high-dose AII infusion. Topics: Angiotensin II; Animals; Blood Pressure; Bridged Bicyclo Compounds, Heterocyclic; Dinoprostone; Dose-Response Relationship, Drug; Fatty Acids, Unsaturated; Hydrazines; Imidazoles; Infusions, Intravenous; Male; Phenoxybenzamine; Phenylephrine; Pressoreceptors; Rats; Rats, Inbred Strains; Saralasin; Thromboxane A2; Thromboxane-A Synthase; Thromboxanes; Urine | 1990 |
Modulation of renin by thromboxane: studies with thromboxane synthase inhibitor, receptor antagonists, and mimetic.
The regulation of plasma renin activity (PRA) by thromboxane (Tx) A2 was studied in anesthetized rats by measuring PRA before and after administration of drugs that block cyclooxygenase (CO) (indomethacin [INDO], 5 mg/kg), thromboxane synthase (TS) (UK 38485 [UK], 100 mg/kg), or Tx receptors (SQ 29548 [SQ], 8 mg/kg or L 641953 [L], 50 mg/kg) or that activate Tx receptors (U 46619 [U], 10 ng.kg-1.min-1). PRA (ng ANG I.ml-1.h-1) was unaffected by vehicle; it was reduced by INDO (25 +/- 2 to 13 +/- 3, n = 13, P less than 0.001) but was increased by UK (24 +/- 3 to 50 +/- 6, n = 18, P less than 0.005), SQ (27 +/- 4 to 44 +/- 7, n = 6, P less than 0.05), and L (32 +/- 4 to 51 +/- 7, n = 10, P less than 0.05). U reduced PRA in each rat (17 +/- 3 to 10 +/- 3, n = 6, P less than 0.005). UK caused dose-dependent stimulation of PRA (mean effective dose 50 mg/kg) and inhibition of TxB2 excretion (mean inhibitory dose 15 mg/kg). After INDO, SQ no longer changed PRA (-1 +/- 10, n = 7). Prolonged administration of SQ for 4-6 days (20 mg.kg-1.day-1 ip) did not change Na+ or K+ balances, blood pressure, renal hemodynamics, or urine flow. However, SQ stimulated PRA (P less than 0.007) independent of prior salt intake. In conclusion in anesthetized rats 1) PRA is stimulated by products of CO but inhibited by products of TS and by a Tx mimetic; 2) stimulation of PRA by SQ depends on ongoing PG and Tx synthesis; 3) rise in PRA with Tx antagonists is not closely related to changes in salt balance, blood pressure, or renal hemodynamics. Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Analysis of Variance; Animals; Blood Pressure; Bridged Bicyclo Compounds, Heterocyclic; Cyclooxygenase Inhibitors; Dibenzothiepins; Fatty Acids, Unsaturated; Glomerular Filtration Rate; Hydrazines; Imidazoles; Indomethacin; Kidney; Male; Prostaglandin Endoperoxides, Synthetic; Rats; Rats, Inbred Strains; Reference Values; Renin; Thromboxane-A Synthase; Thromboxanes | 1989 |
Role of TXA2 in the pathogenesis of severe angiotensin II-salt hypertension.
Urinary TXB2 excretion and the release of TXB2 from vascular and renal cortical tissues are increased in rats with severe AII-salt hypertension. Treatment with an inhibitor of TXA2 synthesis did not change the blood pressure of normotensive or of AII-salt hypertensive rats. Treatment with SQ29,548, a TXA2 receptor antagonist, caused reduction of blood pressure and renal vascular resistance in AII-salt hypertensive but not in normotensive rats. We conclude that the SQ29,548-induced lowering of blood pressure and renal vascular resistance in AII-salt hypertensive rats is the result of blockade of the vascular actions of one or more pressor eicosanoids including TXA2 and the prostaglandin endoperoxides. A corollary of this conclusion is that pressor eicosanoids may be contributory factors in the pathogenesis of severe AII-salt hypertension in rats. Topics: Angiotensin II; Animals; Blood Pressure; Bridged Bicyclo Compounds, Heterocyclic; Fatty Acids, Unsaturated; Hydrazines; Hypertension; Imidazoles; In Vitro Techniques; Kidney; Kidney Cortex; Muscle, Smooth, Vascular; Rats; Reference Values; Sodium, Dietary; Thromboxane A2; Thromboxane B2; Thromboxane-A Synthase | 1989 |
Involvement of prostanoids in the pulmonary pressor effect of histamine.
The role of prostanoids in the pulmonary actions of histamine(HA) was investigated using various antagonists and assay organs in superfusion cascade. Intraarterial injection of HA to the perfused lung caused contractions of rabbit aorta, rat stomach strips, guinea pig trachea, but contraction followed by relaxation of bovine coronary artery, superfused with lung effluent. Lung effluent produced no significant changes in resting tensions of guinea pig ileum or rat colon. The thromboxane synthetase inhibitor, UK 38485, reduced and the thromboxane/prostaglandin receptor antagonist, SQ 29548 abolished HA-induced contractions of all superfused assay tissues. Both contractile and relaxant responses of bovine coronary artery were completely inhibited by indomethacin. The pulmonary pressor effect of HA was also significantly inhibited by all of these antagonists. Our results indicate that HA releases thromboxane A2, prostaglandin endoperoxides, and prostacyclin but not leukotriene and prostaglandin E2- like substances from the guinea pig lung. Topics: Animals; Arachidonic Acids; Biological Assay; Bridged Bicyclo Compounds, Heterocyclic; Cattle; Fatty Acids, Unsaturated; Guinea Pigs; Histamine; Hydrazines; Imidazoles; In Vitro Techniques; Indomethacin; Lung; Pulmonary Artery; Rabbits; Rats; Receptors, Prostaglandin; Receptors, Thromboxane; Thromboxane-A Synthase | 1989 |
Modulating role for thromboxane in the tubuloglomerular feedback response in the rat.
Some studies have indicated that PGs can modulate the single nephron tubuloglomerular feedback (TGF) response. The aim of this study was to define the specific role of the vasoconstrictor PG, TX, by administration to rats of either vehicle (group 1; n = 20) or drugs that inhibit either cyclooxygenase (indomethacin [indo], 5 mg.kg-1, group 2, n = 17), TX synthetase (UK-38,485 [UK], 100 mg.kg-1, group 3, n = 19), or TX receptors (SQ-29,548 [SQ], 8 mg.kg-1, group 4, n = 14, or L-641,953 [L], 50 mg.kg-1, group 5, n = 8). Indo reduced excretion of the prostacyclin derivative 6-keto-PGF1 alpha and TXB2 and lowered whole kidney GFR and renal plasma flow, whereas UK lowered excretion of TXB2 only and did not change basal renal hemodynamics. The TGF response (assessed from reduction in proximal tubule stop-flow pressure (Psf, mmHg) during increases in perfusion of the loop of Henle (LH) from 0 to 40 nl.min-1) was unchanged after vehicle (9.8 +/- 0.5-10.9 +/- 1.0, NS) but blunted (P less than 0.001) by 40-65% in rats of groups 2-5 (indo, 11.1 +/- 1.0-4.4 +/- 0.7; UK, 9.0 +/- 0.8-4.8 +/- 0.7; SQ, 10.3 +/- 0.6-4.8 +/- 0.6; L, 10.7 +/- 0.5-6.7 +/- 1.3). This blunting was due to lower values for Psf at zero LH flow after indo, SQ, and L, and higher values of Psf at 40 nl.min-1 LH flow after indo and UK. The fall in single nephron GFR (SNGFR, nl.min-1) with increasing LH perfusion was unchanged after vehicle (10.9 +/- 2.8-11.2 +/- 0.8) but was blunted (P less than 0.05) by 45-55% in rats given indo (13.9 +/- 1.2-6.2 +/- 2.2) or UK (12.8 +/- 2.1-7.0 +/- 1.5). UK produced dose-dependent reductions in TXB2 excretion (IC50, 15 mg.kg-1) and inhibition of the TGF response (IC50: 30 mg.kg-1). After blockade of TX receptors by SQ, UK had no further affect on the TGF response. The fall in Psf at high LH flow was blunted (P less than 0.05) by indo and UK, whereas the rise in Psf at zero LH flow was blunted by indo, SQ, and L. In conclusion, endogenous TX generation can modulate the reductions in Psf and SNGFR during increased delivery of NaCl to the LH. Topics: Analysis of Variance; Animals; Blood Pressure; Bridged Bicyclo Compounds, Heterocyclic; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Fatty Acids, Unsaturated; Glomerular Filtration Rate; Hydrazines; Hydrostatic Pressure; Imidazoles; Indomethacin; Kidney Glomerulus; Kidney Tubules; Male; Prostaglandins F; Rats; Rats, Inbred Strains; Receptors, Prostaglandin; Receptors, Thromboxane; Thromboxane A2; Thromboxane B2; Thromboxane-A Synthase | 1988 |
Role of pressor prostanoids in rats with angiotensin II-salt-induced hypertension.
This study was designed to assess the contribution of thromboxane A2 to high blood pressure in rats with angiotensin II (Ang II)-salt hypertension. Hypertension was induced in rats drinking 0.15 M NaCl by infusion of Ang II (125 ng/min i.p.) for 12 days. Relative to values in water-drinking rats without Ang II infusion, Ang II-salt hypertensive rats exhibited augmentation (p less than 0.05) of blood pressure (from 129 +/- 3 to 217 +/- 12 mm Hg), urinary thromboxane B2 excretion (from 5.4 +/- 0.9 to 25.4 +/- 2.1 ng/day), and thromboxane B2 release from renal cortex slices (from 71.3 +/- 6.7 to 121.1 +/- 14.4 pg/mg) and aortic rings (from 28.8 +/- 2.9 to 115.8 +/- 12.8 pg/mg). Treatment with an inhibitor of thromboxane A2 synthetase, UK 38485, had no effect on blood pressure in normotensive and Ang II-salt hypertensive rats. Treatment with a thromboxane A2 receptor blocker, SQ 29548, decreased blood pressure in Ang II-salt hypertensive rats from 191 +/- 9 to 152 +/- 9 mm Hg after 3 hours, but it had no effect on blood pressure in normotensive rats. Since SQ 29548 interfered with the pressor effects of the prostaglandin endoperoxide analogue U-46619, prostaglandin F2 alpha, and 9 alpha,11 beta-prostaglandin F2, we suggest that the SQ 29548-induced blood pressure reduction in Ang II-salt hypertensive rats is the manifestation of blockade of the vascular actions of one or more endogenous prostanoids including thromboxane A2 and prostaglandin endoperoxides. If so, pressor prostanoids may be contributory factors in the pathogenesis of severe Ang II-salt hypertension in rats. Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Angiotensin II; Animals; Arteries; Bridged Bicyclo Compounds, Heterocyclic; Dinoprost; Fatty Acids, Unsaturated; Hydrazines; Hypertension; Imidazoles; Kidney Cortex; Male; Prostaglandin Endoperoxides; Prostaglandin Endoperoxides, Synthetic; Prostaglandins F; Rats; Rats, Inbred Strains; Sodium Chloride; Thromboxane A2; Thromboxane B2; Thromboxane-A Synthase | 1988 |
Endothelial injury provokes collateral arterial vasoconstriction: response to a serotonin 2 antagonist, thromboxane antagonist or synthetase inhibition.
To assess the influence on collateral arteries of vasoactive factors released from activated platelets we used angiography and blood flow measurement to study the limb blood supply in 29 rabbits, 2 weeks after superficial femoral artery ligation. Minutes after balloon catheter injury to the lower aorta, striking spasm of the collateral arteries was routinely evident on the arteriograms, and limb blood flow fell. Spasm was partly reversed either by blockade of thromboxane synthesis (UK-38,485) or its vascular action (SQ 29,548) or by ketanserin, the serotonin receptor antagonist when used alone. Ketanserin combined with either UK-38,485 or SQ 29,548 reversed the spasm completely. We conclude that a combined action of serotonin and thromboxane induces collateral artery spasm when platelets are activated. Topics: Animals; Blood Platelets; Bridged Bicyclo Compounds, Heterocyclic; Collateral Circulation; Endothelium, Vascular; Extremities; Fatty Acids, Unsaturated; Hydrazines; Imidazoles; Ketanserin; Rabbits; Serotonin Antagonists; Species Specificity; Thromboxane-A Synthase; Thromboxanes; Vasoconstriction | 1988 |